<DOC>
	<DOCNO>NCT00466921</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth mycosis fungoides/Sezary syndrome block blood flow cancer . PURPOSE : This phase II trial study well lenalidomide work treat patient relapse mycosis fungoides/Sezary syndrome .</brief_summary>
	<brief_title>Lenalidomide Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate duration response patient relapse mycosis fungoides/Sézary syndrome treat lenalidomide . - Determine progression-free survival patient treated drug . Secondary - Determine toxicity drug patient . - Correlate antiangiogenetic costimulatory effect drug clinical activity skin biopsy patient . - Assess specific immune effector cell recruitment augmentation antitumor response patient . ( Northwestern University ) OUTLINE : This multicenter study . Patients receive oral lenalidomide daily day 1-21 . Treatment repeat every 28 day 2 course . Patients progressive disease remove study . Patients achieve complete response receive 2 additional course treatment beyond complete response . Patients achieve partial response stable disease may continue receive lenalidomide 2 year . Treatment continue absence disease progression unacceptable toxicity . Patients undergo tissue biopsy baseline day 1 course 2 . Tissue specimens analyzed vessel density , presence adhesion molecule , immunophenotyping dermal infiltrate . * NOTE : *At Northwestern University , blood tissue sample 5-10 patient collect . Peripheral blood sample analyze immune cell repertoire ( CD4+ , CD8+ T cell , NK cell , NKT cell , CD4+ , CD25+ T-regulatory cell , monocyte , dendritic cell subset ) , cell surface molecule , TH1/TH2-associated cytokine , interleukin ( IL ) -2 , IL-4 , IL-10 , IL-12 , interferon gamma , tumor necrosis factor alpha , flow cytometry baseline , day 15 course 1 , end course 1 . Immunological activation assess analyze surface expression CD45RO CTLA-4 CD4+ CD8+ T cell blood skin sample . Skin specimens stored future research study predictive marker lenalidomide activity . After completion study treatment , patient follow every 3 month 1 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mycosis fungoides/Sézary syndrome Stage IAIVB disease Must fail ≥ 1 prior topical treatment , include follow : Steroids Nitrogen mustard Retinoids Phototherapy Photochemotherapy Radiotherapy Total skin electron beam Measurable disease ≥ 1 indicator lesion designate prior study entry Erythrodermic patient eligible PATIENT CHARACTERISTICS : ECOG performance status 02 WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2.2 mg/dL AST ALT ≤ 2 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile woman must use effective doublemethod contraception ≥ 4 week , , ≥ 4 week completion study therapy Fertile men must use effective contraception ≥ 4 week completion study therapy No malignancy within past 5 year except treat squamous cell basal cell carcinoma skin , carcinoma situ cervix , surgically remove melanoma situ skin ( stage 0 ) , histologically confirm free margin excision current evidence disease No acute infection require systemic treatment No know allergic reaction hypersensitivity thalidomide PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior topical therapy , systemic chemotherapy , biological therapy No prior stem cell transplantation No concurrent systemic antipsoriatic anticancer therapy , include radiotherapy , thalidomide , investigational agent No concurrent topical agent except emollient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
</DOC>